抗血管生成在NSCLC专业技术应用专业技术.pptVIP

;Disclosures;Case #1;She is initially treated with stereotactic XRT for her CNS lesions and comes for systemic therapy. Which chemotherapy regimen is not supported by randomized phase III data? ;Question #1;Case #1;Which maintenance therapy is part of a regimen that has been shown to prolong OS in a randomized phase III study?;Question #2; 12 mo. 24 mo. 43.7% 16.9% 51.9% 22.1% ;Does BV maintenance provide benefit in first-line NSCLC?;JMEN: Outcome in non-squamous histologypemetrexed vs BSC for NSCLC ;ATLAS study design ;ATLAS – progression-free survival ;ATLAS – update on overall survival ;ECOG5508: Phase III trial of BV, Pem, or BV+Pem as maintenance therapy in advanced NSCLC;S130 trial: Phase III trial of CP+Bv?Bv vs PemCarbo+Bv?Pem in first line NSCLC ;Point Break: phase III trial of CP+Bv?Bv vs PemCarbo+Bv?Pem+BV (Sandler vs Patel) in first line NSCLC;AVAPERL1: Phase III BV + Pem as maintenance after cis/pem/BV induction as 1st line therapy;Case #1 continued;She is given a prescription for erlotinib, but asks whether BV should be restarted as well. Which of the following is true? ;Question #3: second-line treatment;Randomized phase III study comparing BV+erlotinib vs erlotinib (BeTa);Randomized phase III study comparing BV+erlotinib vs erlotinib (BeTa);Randomized phase III study comparing BV+erlotinib vs erlotinib (BeTa): greater benefit for BV in EGFR mutants?;Elevated MET and HIF-1a levels in cell lines with mutated EGFR;Regulation of HIF and MET by EGFR;;Phase III study of BV+erlotinib vs erlotinib in EGFR mut+ patients(CALGB31002/CHUGAI A+T);Case #1: third line treatment;Which of the following has been found to be true in phase III testing in 2nd/3rd line NSCLC?;Question #4: third line treatment;Recurrent (stage IIIB/IV) NSCLC afterfailure of first-line chemotherapyTotal recruitment = 1391 patients;PFS in ZODIAC trial;Vandetanib in NSCLC;Summary